Director, International Market Access - Neuroscience

Company Description

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

Job Description

The International Market Access & Pricing (iMAP) Team leads the market access strategies and planning for pipeline as well as on market products.

The Neuroscience space is particularly unique relative to other therapeutic areas as there is a large price disparity for treatments between the US and OUS markets and the evidence requirement to activate each region can be quite different. 

This role will leverage your clinical understanding, expertise of Evidence Based Medicine, alongside deep global payer knowledge, and competitive insights to innovate Phase II/III clinical development programs for pre-launch compounds.  This role will also require complex problem solving and decision quality to navigate the unique challenges within Neuroscience.  The role will also call on you to be a commercial leader as the infrastructure in the disease areas of focus are in early stages of development from an international perspective at Abbvie.

The iMAP director reports to the VP iMAP, Neuroscience and is accountable for the following:

• Defining the International Integrated Access Strategy (IAS) for the Neuroscience Toxin portfolio focused on AGN-607 (next generation toxin), Botox in line business and future toxins building Pricing, Reimbursement and Access (PRA) consistent with the commercial strategy
  • Define a path to optimize the entry on the next generation toxins into an OUS  space where toxins can be commoditized
  • Create IAS for indications such as essential tremor, MDD and HTPFD
  • Establish access pathways in Asian markets like Japan and China where no existing toxin presence exists
  • Support in line efforts on Botox across all of its indications and